BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform

CervoMed Inc. 0.00% Pre

CervoMed Inc.

CRVO

4.04

4.04

0.00%

0.00% Pre

Feb 18 (Reuters) - CervoMed Inc CRVO.O:

  • CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED TO PRIORITIZE PROMISING TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS

  • CERVOMED INC - FIRST ALS PATIENT EXPECTED TO BE DOSED BY END OF 2026

  • CERVOMED: MAINTAIN FOCUS ON DLB, TAKE STEPS TO INITIATE PLANNED PHASE 3 TRIAL LATER THIS YEAR

Source text: ID:nGNX2TdN7K

Further company coverage: CRVO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.